{‘She lacks zero qualifications’: this American healthcare community prepares for Tracy Beth Høeg’s role at the FDA.

As the United States continues making unprecedented changes to its vaccination recommendations, a particular individual has surfaced unexpectedly: Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who first made her name by casting doubt on Covid shots during the pandemic and has focused upon alleged fatalities following Covid vaccination in her short tenure at the FDA.

Proposed Overhauls to Pediatric Immunization Schedule

Health officials planned to unveil major revisions to the childhood immunization program in December, bringing the US with the Danish immunization schedule, sources say – a major change that would place the US out of step with a large portion of the international standard with no evidence for improved outcomes. This reveal has been delayed until the next year.

In place of the top vaccines chief, Tracy Beth Høeg is set to address the audience at the event. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth appointee to head the office this year.

A New Direction at the Agency

The acting appointment could signify a closer partnership between the pharmaceutical and biologics centers as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a renewed priority upon rolling back already-approved immunizations at the FDA.

Dr. Høeg has often pushed for ending some childhood vaccine recommendations in the US in order to be more in line with the Danish model, a society with universal health coverage and a number of inhabitants roughly the size of Wisconsin’s.

So far public appearances, she has persisted in emphasizing on immunizations – usually the domain of Prasad, director of the FDA’s CBER – rather than drug regulation.

Concerns Over Qualifications

Dr. Høeg has no obvious background in pharmaceutical research, approval processes or leadership, which has been standard for past directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the commissioner and CBER since March.

“It seems she lacks to have any of the qualifications” for running the pharmaceutical oversight division, remarked Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in leading a major agency. She has no expertise in drug approvals.”

Previous heads of CBER would “grasp legal statutes and the science of medication creation”, said Janet Woodcock. “Clearly, she lacks the kind of background that former directors who headed the center have had.”

CDER has an immense portfolio at the agency, the former commissioner pointed out.

“Everybody just focuses on the novel medication approvals, but the generic program authorizes thousands of off-brand pharmaceuticals. There’s a biosimilars division, over-the-counter program and so forth, and each of these must be looked after,” she noted. “The thing you overlook, that is precisely what that I always told people is going to bite you.”

Additionally, a substantial administrative element to the position, which manages over 5,000 staff members. “It is a huge administrative position, if you execute it properly,” the former official added.

Response and Controversial Initiatives

Regarding inquiries about Høeg’s qualifications and whether this appointment indicates more teamwork among agency officials on immunizations, a representative responded that the “questions are based on flawed assumptions”.

“Her experience matches the functions of her role,” the official stated, pointing to the time Høeg spent counseling the agency head on “medication safety and approval science, including computational safety modeling and immunization monitoring”.

As acting director, Dr. Høeg inherits the commissioner’s new expedited review system, a disputed rapid medication authorization process that apparently troubled her former heads. “By what process are these therapies being selected for this expedited pathway? Who is making the calls?” Howard asked. “There is a lot of confidentiality occurring at the agency right now.”

Overall, he remarked, “the Food and Drug Administration appears to be shifting towards more relaxed regulations of pharmaceuticals, with the exception of vaccines.”

Established Track Record on Vaccines

Concerning vaccines, Høeg has a more established, if concerning, history, Howard observe. She released a study using non-validated crowd-sourced reports to determine the frequency of myocarditis after Covid immunization. She advised the state of Florida top health official Joseph Ladapo, who was said to have modified findings to imply COVID-19 vaccinations are pose a greater threat than they are.

Among her “policy goals” for the current federal leadership included revising guidelines for recently developed shots and discontinuing “optional” immunizations, she said post-election on a podcast. At the FDA, Dr. Høeg has allegedly proposed barring young men from obtaining COVID-19 vaccines.

“She’s an complete ideologue who begins with her preconceived notions and tailors the evidence to fit the science in a very disingenuous, fraudulent manner,” Howard said.

Consolidating Power and a “Campaign of Retribution”

Høeg aligned with other skeptics, {like|